In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program

Zhonglin Hao; Quan Chen; Bin Huang

doi:10.1093/oncolo/oyad133

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program

Zhonglin Hao
, Quan Chen
, Bin Huang

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	E590
Journal	Oncologist
Volume	28
Issue number	7
DOIs	https://doi.org/10.1093/oncolo/oyad133
State	Published - Jul 2023

Bibliographical note

Funding Information:
Zhonglin Hao reported research funding from Bayer Inc. and consulting/advisory relationships with Pfizer and BeiGene. The other authors indicated no financial relationships.

Funding

Zhonglin Hao reported research funding from Bayer Inc. and consulting/advisory relationships with Pfizer and BeiGene. The other authors indicated no financial relationships.

Funders
Pfizer
Bayer CropScience in Canada

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1093/oncolo/oyad133

Cite this

@article{332626c0037d45529a957e417e958edb,

title = "In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program",

author = "Zhonglin Hao and Quan Chen and Bin Huang",

note = "Funding Information: Zhonglin Hao reported research funding from Bayer Inc. and consulting/advisory relationships with Pfizer and BeiGene. The other authors indicated no financial relationships.",

year = "2023",

month = jul,

doi = "10.1093/oncolo/oyad133",

language = "English",

volume = "28",

pages = "E590",

number = "7",

}

TY - JOUR

T1 - In Reply

T2 - Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program

AU - Hao, Zhonglin

AU - Chen, Quan

AU - Huang, Bin

N1 - Funding Information: Zhonglin Hao reported research funding from Bayer Inc. and consulting/advisory relationships with Pfizer and BeiGene. The other authors indicated no financial relationships.

PY - 2023/7

Y1 - 2023/7

UR - https://www.scopus.com/pages/publications/85164239788

UR - https://www.scopus.com/pages/publications/85164239788#tab=citedBy

U2 - 10.1093/oncolo/oyad133

DO - 10.1093/oncolo/oyad133

M3 - Letter

C2 - 37210565

AN - SCOPUS:85164239788

SN - 1083-7159

VL - 28

SP - E590

JO - Oncologist

JF - Oncologist

IS - 7

ER -

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program

Bibliographical note

Funding

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this